Canada markets closed

Biora Therapeutics, Inc. (BIOR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7310+0.0182 (+2.55%)
At close: 04:00PM EDT
0.7490 +0.02 (+2.46%)
After hours: 06:24PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.7128
Open0.7000
Bid0.7246 x 300
Ask0.7846 x 100
Day's Range0.6700 - 0.7473
52 Week Range0.5850 - 6.7000
Volume266,367
Avg. Volume453,229
Market Cap26.231M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-7.8800
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.30
  • GlobeNewswire

    Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

    Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600, a drug-device combination consisting of the orally administered NaviCap™ device that delivers a proprietary liqui

  • GlobeNewswire

    Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

    Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tractSAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. T

  • GlobeNewswire

    Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

    Mean Plasma Tofacitinib Concentration Following administration of a single oral dose of 5 mg and 10 mg BT-600 All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial is underway and progressing well SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR)